RxDoctor Payments Data

Amando Garza, MD

Internal Medicine · Laredo, TXNPI 1174883177

Payments from drug & device makers

$36,147in general payments, 2019–2025

Across 39 payments — averaging $926.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cleerly, Inc.$36K
  • Amgen$112
  • Novo Nordisk$89
  • AstraZeneca$57
  • Merck$56
  • Lilly USA, LLC$54
  • plus $181 from 9 others

What the payments were for

  • Food & beverage$52696%
  • Education$234%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$36,147 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$144,444
Medicare patients
332
Services billed
1,584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide130$169,393
MounjaroTirzepatide59$76,047
FarxigaDapagliflozin Propanediol66$58,885
JardianceEmpagliflozin41$47,683
TrulicityDulaglutide17$33,060
RybelsusSemaglutide17$32,352
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$5,018
Atorvastatin Calcium371$2,699
Novolog FlexpenInsulin Aspart12$1,787
Losartan Potassium229$1,739
Levothyroxine Sodium170$1,607
Rosuvastatin Calcium171$1,512
Metformin Hcl233$1,218
Pantoprazole Sodium183$1,113
Amlodipine Besylate225$1,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$89$201,746147 claims
Lilly USA, LLCMounjaro, Trulicity$54$109,10776 claims
AstraZenecaFarxiga$57$58,88566 claims
Boehringer IngelheimJardiance$15$47,68341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →